petasiphenol: structure given in first source; bio-antimutagen from scapes of Petasites japonicum [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Petasites | genus | A plant genus of the family ASTERACEAE. Members contain SESQUITERPENES. The common name of sweet coltsfoot is similar to the common name for TUSSILAGO.[MeSH] | Asteraceae | A large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 6438779 |
| MeSH ID | M0211665 |
| Synonym |
|---|
| petasiphenol |
| [3-(3,4-dihydroxyphenyl)-2-oxopropyl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate |
| 3-(3,4-dihydroxyphenyl)-2-oxopropyl caffeate |
| 145904-50-3 |
| 2-propenoic acid, 3-(3,4-dihydroxyphenyl)-, 3-(3,4-dihydroxyphenyl)-2-oxopropyl ester |
| 3-(3,4-dihydroxyphenyl)-2-oxopropyl 3-(3,4-dihydroxyphenyl)prop-2-enoate |
| EN300-26619624 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Petasiphenol did not only inhibit the activity of the truncated pol lambda including the pol beta-like core, in which the BRCT motif was deleted in its N-terminal region." | ( Petasiphenol: a DNA polymerase lambda inhibitor. Asahara, H; Ishidoh, T; Kamisuki, S; Kasai, N; Koiwai, O; Linn, S; Mizushina, Y; Sakaguchi, K; Shimazaki, N; Sugawara, F; Takemura, M; Yoshida, H; Yoshida, S, 2002) | 2.48 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.87) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||